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Cervical cancer is the most common gynecologic 
cancer worldwide [1], more common in low- and 
middle-income countries. It is the second most 
common cancer in incidence among women and 
the third most common cancer in terms of mortal-
ity [2]. The treatment of early stage cervical cancer 
(FIGO stage IB2) has different options described in 
the literature, both primary radiotherapy or surgery 
followed by radiotherapy with or without chemo-
therapy have been validated in different settings [2]. 
High-risk disease includes patients with either 
positive surgical margins, lymph node metastases 
AbstrAct
background: The treatment of early stage cervical cancer has different therapeutic options. adjuvant external beam radio-
therapy for surgically treated intermediate risk cervical cancer patients has shown acceptable oncological outcomes with a low 
incidence of toxicity. The aim of this study was to analyze the oncological outcomes and safety of adjuvant small pelvic field 
radiotherapy in surgically treated stage IB1-2 cervical cancer patients who met the sedlis intermediate-risk criteria.
Materials and methods: a retrospective cohort study was carried out with 28 patients treated from 2007 to November 2019 
with biopsy proven intermediate risk stage IB1–2 cervical cancer previously treated with radical hysterectomy and bilateral 
lymphadenectomy who received adjuvant small pelvic field radiotherapy. The primary endpoints were local and distant con-
trol and overall survival. secondary endpoints were acute and late gastrointestinal and genitourinary toxicity. survival curves 
were analyzed using the Kaplan-Meier method.
results: after a median follow up period of 41.5 (27.5–80.5) months, adjuvant small pelvic field radiotherapy showed a 100% 
overall survival rate, 81.82% disease free survival and 86.36% local recurrence-free survival with no incidence of grade 3 or 4 
acute or late toxicity. Three patients suffered from relapse, 1 in the vaginal cuff, 1 in the retrovesical area and 1 patient in the 
retroperitoneal area.
conclusions: adjuvant small pelvic field radiotherapy is an efficient and safe treatment option that offers excellent onco-
logical outcomes to surgically treated intermediate-risk stage IB1–2 cervical cancer patients with an excellent toxicity profile.
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or parametrial spread, and such patients should 
be offered postoperative radiotherapy with che-
motherapy since the intergroup study 0107 (GOG 
109/SWOG 8797/RTOG 91-12) demonstrated an 
advantage in overall survival when patients receive 
this adjuvant treatment [3]. Surgical pathological 
studies performed by the Gynecologic Oncology 
Group [4–7], identified risk factors that were cat-
egorized as intermediate (tumor size greater than 4 
cm, lymph vascular invasion and stromal invasion 
deep). In the absence of the previously described 
high risk factors, this group of patients benefit from 
adjuvant radiotherapy alone [6, 7]
The classic whole-pelvic field radiotherapy 
(WPRT) is commonly used in most postoperative 
radiotherapy treatments. In this setting, the absence 
of the uterus causes the bowel loops to fall into 
the pelvis, increasing toxicity. It seems reasonable 
to state that directing radiotherapy exclusively to 
the small pelvis would be less toxic than WPRT, 
without compromising oncological outcomes since 
most recurrences occur within the small pelvis [8]. 
This pattern is also supported by the observed nod-
al spread in some surgical series, where the obtura-
tor, internal and external iliac (83.7%) are the most 
common sentinel nodes in early cervical cancer [9], 
followed by the common iliac lymph nodes (6.6%), 
paraaortic (2%) and inguinal (0.07) % [10]. So, the 
most common nodal involvement sites are covered 
within our small pelvic field.
Reports have shown that small field pelvic radio-
therapy offers satisfactory results [11–13] showing, 
as well, a considerable reduction in treatment-relat-
ed morbidity [11–16]. In the present study, postop-
erative cervical cancer patients who met the Sedlis 
[6] criteria and received adjuvant small field pelvic 
radiotherapy were retrospectively analyzed to in-
vestigate its clinical efficacy and safety.
Materials and methods
General clinical data
Patients treated for cervical cancer between 
January 2007 and November 2019 at the Carlos 
Van Buren Hospital, Valparaiso, Chile, were eli-
gible for this study. The study inclusion criteria 
are: ≥ 18 years of age, diagnosed with early stage 
cervical cancer (FIGO 2009 ≤ IB2), presenting at 
least 2 intermediate risk factors (tumor size greater 
than 4 cm, lymph vascular invasion and deep stro-
mal invasion), managed with radical hysterectomy 
plus bilateral lymphadenectomy followed by small 
pelvic field radiotherapy at our institution. We ex-
cluded patients with high-risk features, as well as 
those who had not been treated or followed by 
a gynecologist oncologist.
The primary end points were to determine the 
local and distant control defined as percentage of 
patients without evidence of relapse within the pel-
vis and distant organs as well as overall survival. 
This definition encompasses relapses happening 
from the first day of radiotherapy treatment to the 
date of the last medical appointment. Secondary 
outcomes included toxicity, both acute and late 
genitourinary and gastrointestinal, according to the 
RTOG [17, 18] toxicity grading system. Acute tox-
icity was considered when adverse events occurred 
within 90 days following the start of radiotherapy 
and late toxicity later than 90 days.
radiotherapy protocol
Patients were treated with 3D conformal radio-
therapy using a small pelvic 4-field box technique, 
without brachytherapy. Clinical target volume 
(CTV) was defined as the vaginal cuff with a 2 
cm margin, also including regional lymphnodes 
(bilateral internal iliac, external iliac and obturator 
chains) up to the inferior border of the sacroiliac 
joint. Planning target volume (PTV) was created 
with an isotropic expansion of 1 cm. A visual exam-
ple of the treatment set up can be found in Figure 1. 
All patients were treated with 6–18 MV photon 
beam in a Varian 21iX Linear accelerator with an 80 
multileaf collimator. Dose prescription ranged from 
45 to 50.4 Gray in 1.8 G to 2 Gy daily fractions. 
Treatments were planned using Eclipse 8.6.23. Fol-
low up was every 4 months during the first year, 
every 6 months up to 5 years and then annually.
study design
For this single retrospective cohort, informa-
tion was extracted from the clinical records of 
early stage cervical cancer (FIGO ≤ IB2) patients 
who met the inclusion criteria and received radio-
therapy with a small pelvic field at the radiation 
oncology unit in the Carlos Van Buren hospital. 
Our research was previously approved by the lo-
cal ethics committee. The data were obtained by 
reviewing the records available in the clinical files 
of our facility. 
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statistical analysis
All statistical analysis was performed using STA-
TA 16.1 SE (StataCorp LLC, College Station, TX, 
United States of America). Survival analysis was 
made with the Kaplan-Meier method, estimating 
overall survival, disease-free survival, and local 
recurrence-free survival, all defined from the start 
of radiation therapy. Patients were censored at last 
follow-up visit if they had no evidence of recurrent 
disease. Treatment toxicities were graded under the 
RTOG toxicity grading system [17, 18]. 
results
Between January 2007 and November 2019, 1529 
patients were treated for cervical cancer at our cen-
ter. Inclusion criteria were met by 29 patients; how-
ever, 1 patient was excluded because of incomplete 
surgery, not executed by a gynecological oncologist 
(no lymphadenectomy). The most prescribed ra-
diotherapy dose was 50.4 Gy in 28 fractions to the 
PTV, although 2 patients received 45 Gy and 48.6 
Gy, respectively. The main characteristics of the 
studied patients are described in Table 1.
Median follow up time was 41.5 months (IQR 
27.5–80.5). More than 70% of our population was 
under 50 years of age. The most common histologi-
cal type was squamous cell carcinoma (78.6%). The 
median number of lymph nodes resected was 21 
(14.5–27). Median interval time between the sur-
gery and radiotherapy was 48.5 days (IC 48.5–88.5), 
27 patients were treated with radical hysterectomy 
(96.4%). Median tumor size was 2.8 cm (IC 2.5–3.2) 
with only 2 patients presenting tumors larger than 
4 cm (7.15%). Stromal invasion was classified as 
superficial in 2 patients (7.14%); intermediate in 11 
patients (39.3%) and deep in 10 patients (17.9%). 
Lymph vascular invasion was present in 23 patients 
(82.1%).
Regarding acute toxicity, 15 patients had no GI 
toxicity (53.5%), 6 patients (21.4%) suffered from 
grade 1 GI toxicity and only 7 patients (25%) from 
grade 2. No patients had grade 3 or 4 GI toxicity 
in our study. Genitourinary toxicity was observed 
as follows: 18 patients with no toxicity (64.2%), 9 
patients with grade 1 (32.14%) and only 1 patient 
with grade 2 toxicity (3.5%). Regarding late toxic-
ity, 26 patients (96.29%) had no late GI toxicity and 
only one patient (3.7%) showed grade I toxicity 
with mild digestive symptoms. Genitourinary tox-
icity incidence was also low, with 25 asymptomatic 
patients (93%), 1 patient (3.7%) with grade I toxic-
ity and 1 patient (3.7%) with grade 2 toxicity (mild 
occasional bleeding). Acute and late toxicities can 
be seen in Figures 2 and 3, respectively.
Three patients presented recurrent disease. Two 
of these events where local recurrences. One pa-
tient relapsed within the vaginal cuff 2 years af-
ter treatment; 1 patient in the retro vesical area 4 
years after treatment; and 1 patient suffered from 
a retroperitoneal relapse located left from the L3-L4 
junction. Five-year overall survival was 100% and 
Figure 1. Treatment set up. purple — clinical target volume (cTV); red — planning target volume (pTV)
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5-year disease-free survival was 81.82% (CI 95%: 
51.9–94.03), with a local recurrence-free survival of 
86.36% (CI 95%: 53.61–96.61) (Fig. 4).
Discussion
Small pelvic field radiotherapy is a valid tech-
nique with excellent oncological outcomes and 
comparable with other conventional treatments in 
surgically managed cervical cancer patients with 
intermediate risk factors.
Relevant publications and their outcomes are 
summarized in Table 2. We found that our results 
are comparable with those of Kridelka et al. [12] 
who used small pelvic field in 25 intermediate risk 
patients with only 1 local recurrence. In this study, 
the upper limit of the field was located in the S1-S2 
intersection. In addition, the study demonstrated 
a significant improvement in 5-year DFS for the 
group that received adjuvant small field pelvic ra-
diation compared to the observation group. Hong 
et al. [13] investigated whether postoperative radia-
tion therapy to the lower pelvis is an appropriate 
treatment for patients with early high-risk cervical 
cancer with negative nodes. Seventy-nine patients 
table 1. patients characteristics
Characteristic Patients, n (%)*
age, years Median 47, IQr 36.5–56
≤ 50 17 (60.7)
> 50 11 (39.3)
type of surgery
radical hysterectomy 27 (96.4)
Trachelectomy 1 (3.6)
resected lymph nodes Median 21, IQr 14.5–27
Interval between surgery  
and radiotherapy, days
Median 48.5, IQr 48.5–88.5
prescribed radiation dose, Gray Median 50.4, IQr 50.4–50.4
radiotherapy length, days Median 39, IQr 37.5–41.5
Tumor size, centimeters Mean 2.86, cI 2.5–3.2
≤ 2 5 (17.9)
2–4 21 (75)
> 4 2 (7.15)
Histopathology
squamous cell carcinoma 22 (78.6)
adenocarcinoma 3 (10.7)
adenosquamous carcinoma 2 (7.1)







Up to 1/3 2 (7.14)
Up to 2/3 11 (39.3)
Up to 3/3 10 (35.7)
N/a 5 (17.9)
Lymph vascular space 
involvement
23 (82.1)
*Or central tendency measures where appropriate; IQr — interquartile 
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Figure 2. Bar graph reporting radiotherapy acute toxicity 
in the treated population for both gastrointestinal and 
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Figure 3. Bar graph reporting radiotherapy late toxicity 
in the treated population for both gastrointestinal and 
genitourinary complications using the rTOG grading 
system
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received whole-pelvic radiotherapy and a boost 
dose in the lower pelvis and 149 patients received 
low-pelvic RT alone. Results showed a 5-year overall 
and disease-specific survival rate of 84% and 86%, 
respectively. In comparison, our results revealed 
more favorable outcomes, which can be explained 
by the fact that we only treated intermediate risk 
patients. Ohara et al. [11] examined whether the 
use of a small pelvic field reduces the adverse events 
that occur with the classic whole pelvic field. The 
5-year pelvic disease control rate for node-negative 
patients and node-positive patients was 93% versus 
90%, respectively. Acute diarrhea (Grades 2–3) oc-
curred significantly more often in the whole pelvic 
group (32.4%) compared to the small pelvic field 
group (9.2%). Regarding late events, only ileus oc-
curred at a significantly higher rate in the whole 
pelvic group than in the small pelvic field group 
(16.2% vs. 3.2%). In our cohort no episodes of ileus 
were reported. Although both studies were retro-
spective, their results show similar local pelvic con-
trol with reduced treatment-related toxicity. Sari et 
al. [16] investigated whether small field adjuvant 
radiation therapy is sufficient in patients with early 
cervical cancer with intermediate risk factors. They 
retrospectively evaluated 113 patients, and all were 
treated with small-field pelvic RT. The upper limit 
of the field was the L5–S1 intervertebral space, but 
table 2. summary of small pelvic field radiation studies
Treatment Author Stage No. of patients End point 1 End point 2
adjuvant sprT alone Kridelka et al. IB negative nodes 25 DFs at 5 y: 96%
adjuvant rT low pelvis 
vs. Whole pelvis
hong et al. I to II negative nodes 228 Os at 5 y: 84% Dss at 5 y: 86%*
adjuvant sprT vs. WprT Ohara et al. T1b–T2a 72
5-year pelvic disease 
control rate for node- 
-negative patients: 93%*
IMrT sprT vs. WprT Luo et al. Ia1 – IB1 371 Os at 5 y: 91.6% DFs at 5 y: 89.3%*
adjuvant sprT
alone
sari et al. Ia2 – IIa2 113 Os at 5 y: 82% DFs at 5 y: 74%.
adjuvant sprT alone present study Ib — Intermediate risk  28                 Os at 5y: 100% DFs at 5 y: 81.82%
sprT — small pelvic field radiation therapy; WprT — whole pelvis radiation therapy; DFs — disease-free survival; Os — overall survival; Dss — disease-specific 
survival. *No significant difference between the treatment arms
Figure 4. A. Five-year disease-free; b. Local recurrence-free survival
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the lower edge is just inferior to the iliac foramina; 
that is, relatively smaller than conventional fields. 
The results showed an excellent pelvic control rate 
of 90.3% at 2 years with no severe gastrointesti-
nal toxicity. These results are comparable to ours 
regarding disease control and safety. This finding 
supports that small field adjuvant pelvic RT is an 
adequate and sufficient treatment for patients with 
intermediate risk factors, in addition to providing 
clinical safety. At the same time, we highlight the 
fact that we used even tighter limits regarding field 
coverage without compromising pelvic control, as 
seen in our results.
In order to identify optimal candidates for small 
pelvic field radiotherapy Yeo et al. [14] performed 
a retrospective analysis of cervical cancer patients 
with FIGO stage IB to IIA who had undergone 
radical hysterectomy and lymphatic dissection. 
Patients without high risk factors would be clas-
sified according to the GOG score. Based on the 
score obtained, only observation, small-field ra-
diation therapy, or standard field radiation therapy 
was recommended as obtaining excellent outcomes. 
Luo et al. [15] evaluated 371 patients with early 
cervical cancer, with at least one of the Sedlis cri-
teria and without high risk factors for recurrence. 
All patients were treated with intensity modulated 
radiotherapy. Two hundred thirty-nine patients un-
derwent whole pelvic radiotherapy, and 132 had 
reduced-volume pelvic radiotherapy. Incidence of 
upper and lower gastrointestinal symptoms with 
whole-pelvis radiotherapy was 94.5 and 96.6%, 
respectively, compared with 71.2 and 81.8% for 
reduced-volume pelvic radiotherapy. Morbidity of 
this treatment appears to be acceptably low and 
significantly less than that associated with standard 
field pelvic radiation. This proves that even with 
the use of more sophisticated technologies, such as 
IMRT, the treatment volume in the pelvis remains 
an important prognostic factor for gastrointestinal 
toxicity. Currently, there are no studies comparing 
small field radiotherapy using 3DCRT vs IMRT, 
although it would be hard to justify the use of in-
tensity modulated therapy with such a low toxicity 
incidence using 3D treatment. 
Our work sets up a starting point to validate 
a simple technique suitable for other treatment mo-
dalities in the future, such as hypofractionation. In 
this scenario, patients could be treated in shorter 
periods of time, and if the treated volumes are redu-
ced, the odds of both acute and late toxicity should 
be reduced.
Only one of the recurrences occurred outside 
the CTV, with a location left from the L3–L4 verte-
bral junction. It should be noted that this location 
would also be missed by a conventional, whole-pel-
vis treatment plan, with an upper limit for the CTV 
at the L4–L5 junction.
The weakness of our work is based on the retros-
pective nature of its design, and a limited number 
of included patients since the studied scenario is an 
uncommon one. As a strength, all of our patients 
were treated and followed by gynecologist-oncolo-
gists and we only considered their follow up appo-
intments as valid when they were carried out at 
cervical pathology units so that all the obtained 
data from follow up visits was registered by expert 
physicians.
conclusion
We conclude that external beam small pelvic 
field radiotherapy without brachytherapy offers 
excellent oncological outcomes showing compa-
rable local and distant control to the other con-
ventional treatments in surgically managed cer-
vical cancer patients with intermediate risk fac-
tors. Since the execution of the technique and the 
equipment needed are highly available, we support 
small pelvic field radiotherapy (RT) as an alterna-
tive modality to reduce toxicity in centers which 
do not count with more modern RT techniques 
such as IMRT. 
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